You are here

  • Home
  • Archive
  • Volume 81, Issue 11
  • Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort’’ by Mastrolia et al

Article Text

Article menu
Download PDFPDF
Correspondence response
Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort’’ by Mastrolia et al
  1. Charlotte Borocco1,2,
  2. Marie Pouletty3,
  3. Caroline Galeotti1,
  4. Ulrich Meinzer3,4,
  5. Albert Faye3,5,
  6. Isabelle Koné-Paut1,2,
  7. Naim Ouldali3,5,
  8. Isabelle Melki3,6,7
  1. 1 Department of Paediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, AP-HP, Le Kremlin-Bicetre, France
  2. 2 University of Paris Sud Saclay, Paris, France
  3. 3 General Pediatrics, Infectious Disease and Internal Medicine Department, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Hôpital Robert Debre, AP-HP, Paris, 75019, France
  4. 4 Center for Research on Inflammation, UMR1149, INSERM, Paris, France
  5. 5 UMR 1123, ECEVE, INSERM, Paris, France
  6. 6 Laboratory of Neurogenetics and Neuroinflammation, Institute Imagine Institute of Genetic Diseases, Paris, France
  7. 7 Pediatric Hematology-Immunology and Rheumatology Department, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Hôpital Necker-Enfants Malades, AP-HP, Paris, France
  1. Correspondence to Dr Isabelle Melki, General Pediatrics, Infectious Disease and Internal Medicine Department, Reference center for Rheumatic, AutoImmune and Systemic diseases in children (RAISE), Hôpital Robert-Debré, AP-HP, Paris, 75019, France; isabelle.melki{at}aphp.fr

https://doi.org/10.1136/annrheumdis-2020-218814

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Mastrolia et al for sharing the paediatric tuscany network (PTN) experience during the first wave of SARS-CoV-2 and their survey to detect the incidence of paediatric inflammatory multisystem syndrome temporally associated with SARS-COV-2 (PIMS-TS) and the rise of Kawasaki disease (KD).1 Interestingly, PTN did not observe any increase in the number of cases of KD and no cases of PIMS-TS in their region between 1 February to 30 June 2020, unlike the many cases described across Europe, North America and Africa.2–9 We believe that several points should be discussed to understand these findings.

    First, as notified by our colleagues from PTN, Tuscany has been relatively preserved by the SARS-CoV-2 epidemic compared with the northern regions of Italy. Thus, on 30 June 2020 at the end of this survey, the Italian Ministry of Health10 reported 93 901 cases of COVID-19 in Lombardy, where cases of PIMS-TS were described,3 compared with 10 250 cases in Tuscany. An epidemiological …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Collaborators Great Paris Region (GPR) Kawa- COVID-19 consortium: Marion Caseris, Brigitte Bader-Meunier, Johanna Lokmer, Cherine Benzouid, Constance Beyler, Romain Basmaci, Noémie Lachaume, Philippe Bensaid, Samia Pichard, Guislaine Carcelain, Mehdi Oualha, Zahir Amoura, Julien Haroche, Juliette Chommeloux, Fanny Bajolle, Stéphane Bonacorsi, Corinne Pondarre, Arielle Maroni, Hanane Kouider, Guillaume Morelle, Irina Craiu, Anna Deho.

    • Contributors CB, NO, MP and IM designed the study and wrote the paper. All authors collected clinical data. CG, AF, UM and IK-P supervised the study. All authors have read final approval of the version published.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles